Form 13-F position report

ALNYLAM PHARMACEUTICALS INC

Reported by STEELHEAD PARTNERS LLC

ALNY 1 09/15/27 CUSIP 02043QAB3 Manager CIK 0001133521

Reported 73,080,000 shares, up 8,080,000 (12.4%) from the prior quarter.

Reported value 1.8%; share count 12.4% vs. the prior quarter.

Added
% of reported 13F value 4.92% This manager · Q3 2026
Shares 73,080,000 Quarter-end amount reported
Reported value $79,565,850 Fair value at quarter end
Consecutive quarters held 3 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2023-09-30 51119475
2023-12-31 54514900
2024-03-31 32865350
2024-06-30 28569518
2024-09-30 0
2024-12-31 6940733
2025-03-31 49632535
2025-06-30 84641050
2025-09-30 0
2026-03-31 77115420
2026-06-30 78157560
2026-09-30 79565850

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for ALNYLAM PHARMACEUTICALS INC held by STEELHEAD PARTNERS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 73,080,000 +8,080,000 (12.4%) 4.92% $79,565,850 2026-11-13
Q2 2026 Added 65,000,000 +5,000,000 (8.3%) 5.57% $78,157,560 2026-08-14
Q1 2026 New 60,000,000 +60,000,000 (0.0%) 5.54% $77,115,420 2026-05-13
Q3 2025 Reduced 0 -65,000,000 (-100.0%) 0 $0 2025-11-14
Q2 2025 Added 65,000,000 +22,000,000 (51.2%) 4.26% $84,641,050 2025-08-14
Q1 2025 Added 43,000,000 +36,500,000 (561.5%) 2.86% $49,632,535 2025-05-15
Q4 2024 New 6,500,000 +6,500,000 (0.0%) 0.35% $6,940,733 2025-02-18
Q3 2024 Reduced 0 -26,500,000 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 26,500,000 -8,500,000 (-24.3%) 1.48% $28,569,518 2024-08-14
Q1 2024 Reduced 35,000,000 -20,000,000 (-36.4%) 1.73% $32,865,350 2024-05-15
Q4 2023 Unchanged 55,000,000 0 (0.0%) 2.83% $54,514,900 2024-02-14
Q3 2023 New 55,000,000 +55,000,000 (0.0%) 2.99% $51,119,475 2023-11-14

Who else reported the position

55 managers reported ALNYLAM PHARMACEUTICALS INC for Q3 2026.

Managers reporting ALNYLAM PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AMUNDI Unchanged 5,000,000 0 0.11% $540,369,010 13 qtrs
STEELHEAD PARTNERS LLC This report Added 73,080,000 +8,080,000 4.92% $79,565,850 3 qtrs
BNP PARIBAS FINANCIAL MARKETS Added 190,841 +42,978 0.02% $59,027,857 12 qtrs
SONA ASSET MANAGEMENT US LLC New 45,440,000 +45,440,000 1.33% $49,464,030 1 qtr
DeepCurrents Investment Group LLC Added 26,000,000 +2,000,000 0.81% $28,292,000 3 qtrs
FMR LLC Unchanged 0 0 < 0.01% $19,879,096 13 qtrs
MACKAY SHIELDS LLC Reduced 14,813,000 -21,000 0.58% $16,039,422 13 qtrs
MANUFACTURERS LIFE INSURANCE COMPANY THE Added 14,400,000 +600,000 0.01% $15,868,800 6 qtrs
ADVENT CAPITAL MANAGEMENT DE Added 14,521,000 +13,671,000 0.36% $15,736,137 2 qtrs
BNP Paribas Asset Management Holding S A Added 9,550,000 +9,516,632 0.01% $10,477,417 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
NOTE 1.000% 9/1

Voting authority reported

Sole
73,080,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.